DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Sunday. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright lowered their price target on DBV Technologies from $20.00 to $10.00 and set a buy rating for the company in a report on Wednesday, May 8th.

DBV Technologies Stock Down 1.4 %

DBVT stock opened at $0.95 on Friday. DBV Technologies has a twelve month low of $0.84 and a twelve month high of $4.08. The firm has a market cap of $91.46 million, a price-to-earnings ratio of -1.13 and a beta of 0.69. The business’s fifty day simple moving average is $1.14 and its two-hundred day simple moving average is $1.50.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.16. The company had revenue of $1.41 million for the quarter, compared to the consensus estimate of $3.20 million. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. Research analysts expect that DBV Technologies will post -1.22 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. increased its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.